04:54 AM EST, 12/17/2025 (MT Newswires) -- Sanofi ( SNY ) said Wednesday its investigational efdoralprin alfa fusion protein has received the European Medicines Agency's orphan drug designation to potentially treat alpha-1 antitrypsin deficiency-related emphysema, a rare respiratory condition.

The decision was based on efdoralprin alfa meeting all primary and secondary endpoints in a global phase 2 trial.

Efdoralprin alfa has already received the US Food and Drug Administration's fast track and orphan drug designations, the company said.